Amarin Corporation Plc (NASDAQ:AMRN)

Amarin Corporation plc (Amarin), incorporated on March 1, 1989, is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).

The MARINE trial is conducted with omega-3 fatty acids in treating patients with very high triglycerides, is a Phase-III, multi-center, placebo-controlled, randomized, double-blind, 12-week study. Patients enrolled in the MARINE trial were given the option to be treated with AMR101 for a period of up to 40-weeks after their last dose in the pivotal trial. The ANCHOR trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study in patients with high triglycerides who were on optimized statin therapy. In April 2011, it reported top-line results from the ANCHOR trial. Prior to commencing the MARINE and ANCHOR trials, it conducted a pre-clinical program for AMR101, including toxicology and pharmacology studies. In addition to the MARINE and ANCHOR trials, it completed a 28-day pharmacokinetic study. It is also focusing development of other compounds based on its internal lipid science expertise.

The Company competes with GlaxoSmithKline plc, Abbott Laboratories, Pronova BioPharma Norge AS, Apotex Corp., Apotex Inc., Omthera Pharmaceuticals, Trygg Pharma, Neptune Technologies & Bioresources Inc., Resolvyx Pharmaceuticals and Catabasis Pharmaceuticals.

Web site: http://www.amarincorp.com/

Last updated July 30, 2012